PT-141

PT-141 10 mg is PrimeTime BioLabs' research-supply listing for the peptide commonly referred to in scientific and laboratory contexts as PT-141, and by its generic name, bremelanotide. The "PT-141" designation originated during the compound's early research and development history and is still the name most researchers use when searching for or discussing the material; "bremelanotide" is the standard chemical/generic name used in pharmacological and regulatory literature. This listing supplies 10 mg of material per vial, which is the quantity denoted directly in the product name and confirmed on this page. The vial is packaged in lyophilized (freeze-dried) form. Lyophilization is a standard method for stabilizing peptide material for storage and transit, since removing moisture significantly slows the chemical degradation pathways that affect peptides in solution. PrimeTime seals each vial to be light-protected, since many peptides — bremelanotide included — are sensitive to photodegradation over time. Every vial carries a lot-specific label, which ties that individual unit to a batch number and, in turn, to a Certificate of Analysis for that specific batch. This lot-to-COA relationship is what allows a researcher to confirm that the documentation they are reviewing actually corresponds to the material in their hands, rather than a generic or historical test result. Each unit is intended as a single-use research quantity — the listing does not represent a multi-dose treatment kit, a reconstitution kit, or a consumer product, and PrimeTime does not supply guidance for human dosing, injection, or administration, because the material is not distributed for that purpose. Researchers working with PT-141 are expected to determine their own protocols in accordance with their institution's research procedures and applicable regulatory requirements for handling research-use-only compounds. It's worth being direct about what this listing is not. It is not a prescription pharmaceutical, it is not dispensed against a prescription, and it is not represented as equivalent to any FDA-approved drug product built on the same underlying compound. The distinction matters because "PT-141" and "bremelanotide" both appear prominently in searches tied to an approved prescription medication (discussed further in the Compliance Notice below), and conflating the two — a common issue across supplier sites — creates real confusion for researchers trying to source material for legitimate laboratory work. PrimeTime's position is narrower and more specific: this is a research-use peptide, sold with documentation, to buyers who are sourcing it for laboratory purposes. For institutions or research groups with recurring material needs, PrimeTime notes that bulk pricing is available on select bundles — contact the PrimeTime team directly to discuss quantity requirements for a given research program.

PT-141 (bremelanotide) belongs to a class of synthetic peptides derived from analogs of alpha-melanocyte-stimulating hormone (α-MSH), and it is classified in the scientific literature as a melanocortin receptor agonist. The melanocortin receptor family includes five subtypes (MC1R through MC5R), and published pharmacological research has focused substantially on the compound's activity at MC3R and MC4R, both of which are expressed within the central nervous system. This is the basis for the distinction PrimeTime draws on this page: bremelanotide's studied mechanism operates through central melanocortin receptor signaling rather than through the peripheral vascular pathways that other, structurally unrelated compounds are studied for. That distinction is well established in the pharmacology literature and is a meaningful point of scientific differentiation — it is not a claim about what this specific research material does in a human being, and PrimeTime does not represent it as one. It's important to separate three different things that often get blurred together in supplier content: the underlying compound's chemistry, the body of published research on that compound (including research conducted on an FDA-approved drug product built from the same compound), and this specific PrimeTime research listing. PubChem and other authoritative chemical databases document bremelanotide's structure as a synthetic cyclic peptide — commonly described as a heptapeptide — built on an α-MSH-derived backbone, with a formula, molecular weight, and CAS number associated with its free-base form. A related acetate salt form is documented separately in chemical references, with its own distinct formula and CAS number; free-base and acetate forms are not interchangeable, and the two should never be treated as the same specification. PrimeTime's current product page does not publish a sequence, molecular formula, molecular weight, or CAS number for this specific listing, so none of those free-base or acetate-specific values are stated here as a PrimeTime product specification — a researcher who needs that exact data point for this lot should request it directly or consult the item's Certificate of Analysis and product documentation. Separately, bremelanotide has a clinical and regulatory history of its own: it underwent human clinical trials and received FDA approval in 2019 as a prescription injectable (marketed as Vyleesi) for a specific indication in a defined patient population. That regulatory and clinical history exists independently of this listing. PrimeTime BioLabs does not distribute Vyleesi, does not represent this product as equivalent to an approved drug product, and does not make any claim about outcomes, effects, or performance of this material outside of a laboratory research context. Published clinical and receptor-level research on the compound is a useful reference point for understanding why bremelanotide is studied at all — it does not describe or validate what happens when this specific research-use material is used, because it isn't intended to be used outside of qualified research settings in the first place.

PrimeTime BioLabs states that each lot of PT-141 10 mg is third-party tested for purity, identity, and sterility before it ships, and that Certificate of Analysis (COA) documentation is available for download so a researcher can confirm the specifications tied to their exact batch. The COA for the current listed batch is linked directly on this page, and it reports the batch number, the purity result, and the date the lot was analyzed. It's worth explaining plainly what that kind of documentation can and can't tell a researcher, because it's easy to over-read a test result. Purity and identity testing characterizes the material that was tested, under the specific method and conditions used for that test — it indicates how consistent the tested sample was with the expected compound, and what proportion of the sample was accounted for by that compound under the reported method. It does not, on its own, establish biological activity, potency in any living system, safety, or clinical effect. Sterility testing addresses whether a sample shows evidence of microbial contamination under the conditions tested; it is a quality-control measure, not a certification that a material is appropriate for any particular use. None of this testing constitutes, implies, or substitutes for regulatory approval, and a passing analytical result on a research compound says nothing about the safety or efficacy profile of an approved pharmaceutical product built on a related compound. Because testing is lot-specific, the exact purity figure that applies to a given order is the one shown on that batch's COA rather than any general purity language elsewhere on the page — batch documentation is the authoritative source, and researchers who need a precise, audit-ready figure for their own records should reference the COA tied to the lot number on their vial rather than summary language. If a discrepancy ever appears between the on-page badge and the linked COA for a given batch, the COA governs, since it is the lot-specific analytical record. PrimeTime ties each COA to a batch number that also appears on the vial's physical label, which is what allows a researcher to confirm — unit by unit — that the documentation on file actually corresponds to the specific vial in front of them, rather than a general or historical reference document for the product line.

PT-141 10 mg is distributed by PrimeTime BioLabs exclusively for qualified laboratory and in-vitro research purposes. It is not a drug, dietary supplement, or cosmetic product. It carries no FDA approval as a PrimeTime product, and PrimeTime does not represent it as equivalent to, or a substitute for, Vyleesi or any other FDA-approved bremelanotide-based drug product. This material is not intended for human consumption, human use, or animal use of any kind, and it is not intended for diagnostic or therapeutic use. This listing should be handled only by trained laboratory personnel operating within an appropriate research setting, in accordance with their institution's protocols and any applicable regulatory requirements governing research-use-only compounds. PrimeTime does not provide dosing information, administration guidance, injection instructions, or treatment protocols for this product, because it is not sold, marketed, or intended for those purposes. By purchasing PT-141, the buyer represents that they are acquiring the material for legitimate research purposes and that they understand and accept these restrictions. Researchers with questions about a specific batch's documentation, or about PrimeTime's research-use policies more broadly, can reach PrimeTime directly through the contact channels listed on the site.